Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021. “Many people with mild-to-moderate plaque psoriasis still report …
Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
Today
A mix of clouds and sun early, then becoming cloudy later in the day. High 66F. Winds WSW at 5 to 10 mph..
Tonight
Rain. Low 47F. Winds ESE at 5 to 10 mph. Chance of rain 100%. Rainfall near a half an inch. Locally heavy rainfall possible. Updated: April 24, 2021 @ 1:58 am
Bimekizumab Tops Secukinumab for Adult Plaque Psoriasis medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DURHAM, N.C., April 23, 2021 /PRNewswire/ Burt s Bees, a pioneer in natural skin care, today announced its latest research findings on the benefits of nature-based ingredients to address today s evolving skincare needs. The data will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021) from April 23-25, 2021.
The latest research findings from Burt s Bees highlight:
For Burt’s Bees, the power of nature meets the proof of science at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).
Burt’s Bees, a pioneer in natural skin care, today announced its latest research findings on the benefits of nature-based ingredients to address today’s evolving skincare needs.
2.0 (2.4)
Participants included 1,174 patients from ECZTEND at data cut-off.1 Observed outcomes for all patients enrolled 60 weeks prior to data cut-off (n=513) were analyzed at Week 56.1 At parent-trial baseline, ECZTEND baseline, and Week 56, median EASI score was 26.6, 4.7, and 1.8, respectively.1 At Week 56, IGA and EASI response rates were 49.7% (IGA 0/1), 95.1% (EASI-50), 82.8% (EASI-75), 61.0% (EASI-90), and 79.7% (EASI ≤7). An EASI score of ≤7 corresponds to mild atopic dermatitis.1
At the same 56-week data cut-off, measurements of itch and sleep disruptions due to itch were also reported.1 At Week 56, the mean worst weekly pruritus (i.e. itch) numeric rating scale (NRS) score was 3.3 (parent-trial baseline was 7.7) while the mean eczema-related weekly sleep NRS score was 2.0 (parent-trial baseline was 6.9).1